Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Details : BEAM-201 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 18, 2025
Lead Product(s) : BEAM-301
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BEAM-301 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glycogen Storage Disease Type I.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 16, 2024
Lead Product(s) : BEAM-301
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BEAM-101,Busulfan
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy
Details : BEAM-101 is a cell therapy which increases the production of fetal hemoglobin (HbF), was being investigated in patients with sickle cell disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 05, 2024
Lead Product(s) : BEAM-101,Busulfan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BEAM-302
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BEAM-302 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of alpha 1-Antitrypsin Deficiency.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : BEAM-302
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VERVE-101
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : $600.0 million
Deal Type : Acquisition
Details : Eli Lilly acquire certain rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease, which includes programs, VERVE-101, targeting PCSK9, ANGPTL3 and an undisclosed liver-mediated, cardiovascular target.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $250.0 million
October 31, 2023
Lead Product(s) : VERVE-101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : $600.0 million
Deal Type : Acquisition
Lead Product(s) : BEAM-201,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BEAM-201 is a quadruplex base-edited, anti-CD7 allogeneic chimeric antigen receptor T cell (CAR-T) under clinical investigation for the treatment of CD7+ relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 05, 2023
Lead Product(s) : BEAM-201,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BEAM-201
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BEAM-201 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : BEAM-201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ESCAPE-1 consists multiplex base edited HSCs including therapeutic edit for SCD at the HGB1/2 gene and an additional edit at CD117. ESCAPE antibodies binds to wild-type CD117 and blocks binding of its ligand.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RNA-Based Vaccine
Therapeutic Area : Technology
Study Phase : Discovery
Recipient : Orbital Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RNA-based medicines represent fast-growing and disruptive class of therapeutics for a breadth of disease areas. First-generation RNA treatments successfully overcame multiple hurdles, such as the rapid degradation of exogenous RNA, delivery of RNA.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 07, 2022
Lead Product(s) : RNA-Based Vaccine
Therapeutic Area : Technology
Highest Development Status : Discovery
Recipient : Orbital Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Orbital Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of its launch, Orbital and Beam Therapeutics have entered into a license and research collaboration under which Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Orbital Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration